MRSA/Drug Resistance News

Improved Targeting Using Sugar-Coated Antibiotics

Sat, 21 Jun 2008 18:00:05 GMT

Researchers from the John Innes Centre and the University of East Anglia have recently elucidated the structure and function of an enzyme which is involved in decorating antibiotics with sugar molecules.

Full text

EPA Registered Disinfectant Kills Both Known Types Of MRSA

Fri, 20 Jun 2008 14:00:09 GMT

While MRSA has been an issue in healthcare settings for years, CA-MRSA outbreaks in the community have been on the rise, with the greatest risk in community settings such as fitness clubs, in sports teams, at schools and daycare centers.

Full text

The Genome Of A Newly Emerging Superbug Reveals An Organism With A Remarkable Capacity For Drug Resistance

Fri, 20 Jun 2008 14:00:08 GMT

The genome of a newly-emerging superbug, commonly known as Steno, has just been sequenced. The results reveal an organism with a remarkable capacity for drug resistance.

Full text

Funding For Superbug Spin-Out

Fri, 20 Jun 2008 14:00:05 GMT

Procarta Biosystems, the company spun-out of the John Innes Centre in 2007 to develop a technology designed to defeat antibiotic-resistant superbugs, has received significant seed funding.

Full text

Forest Laboratories Announces Positive Results From Phase III Clinical Studies Of Ceftaroline For The Treatment Of Complicated Skin Infections

Fri, 20 Jun 2008 14:00:02 GMT

Forest Laboratories, Inc. (NYSE: FRX) announced positive results from two globally conducted, multi-center Phase III studies of ceftaroline, a broad-spectrum cephalosporin with activity against gram-positive bacteria, such as MRSA and gram negative bacteria, for the treatment of complicated skin and skin structure infections (cSSSI).

Full text

NovaBay NBY Announces Positive Results From Phase IIA Study Of AgaNase TM For Nasal Decolonization Of Staph Including MRSA

Thu, 19 Jun 2008 10:40:04 GMT

NovaBay Pharmaceuticals, Inc. (AMEX & TSX: NBY) a clinical stage biopharmaceutical company, announced top line results from a Phase IIa exploratory clinical trial for NVC-422, the company's lead non-antibiotic antimicrobial Aganocide compound, which is being developed for the prevention and treatment of infections.

Full text

Nationwide Progress Poll Reveals Increased Efforts By Hospitals To Control MRSA Infection

Thu, 19 Jun 2008 10:40:02 GMT

More than three out of four (76%) infection prevention and control professionals (ICPs) polled indicated they have implemented additional measures to prevent the transmission of methicillin-resistant Staphylococcus aureus (MRSA) in the last year, but 54% said their institutions are not.

Full text

Research Priorities To Fight Drug-Resistant Tuberculosis

Wed, 18 Jun 2008 07:00:08 GMT

Tuberculosis (TB) has long been one of the world's great killers. Now, forms of drug-resistant TB--multidrug (MDR) and extensively drug-resistant (XDR)--are occurring at an ominous and accelerating rate.

Full text

Global Risk - Infection By Deadly Bacterium Can Be Prevented With Proper Sanitation

Tue, 17 Jun 2008 03:40:05 GMT

As urban sprawl spreads throughout the globe, so do poor urban ghettos and the infectious diseases that are perpetrated by unsanitary slum conditions.

Full text

Bacteria Can Be Spread By Antibacterial Wipes

Tue, 17 Jun 2008 03:40:04 GMT

A new study by a team of researchers at the Welsh School of Pharmacy, Cardiff University, Wales, UK, has found that antimicrobial-containing wipes currently used to decontaminate surfaces in hospitals can spread pathogens after first use.

Full text